A Novel Urine Cytology Stain for the Detection and Monitoring of Bladder Cancer

Davis, N S; Mor, Yoram; Idelevich, Pavel; Terkieltaub, Dov; Ziv, Vivi; Elkeles, Adi; Lew, Sylvia; Okon, Elimelech; Laufer, Menachem; Ramon, Jacob; Kedar, Daniel; Baniel, Jack; Yossepowitch, Ofer

doi:10.1016/j.juro.2014.06.079

Cited by 13 publications

(6 citation statements)

References 14 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the CellDetect assay is a novel histochemical staining platform which allows for the discrimination between normal and malignant cells on the basis of color and morphological discrimination-based on the higher metabolic activity in cancer cells [39]. An Israeli study across 9 hospitals employing urine smears found that the overall sensitivity of this test was 84%, and the specificity was also 84% for patients undergoing routine surveillance by cystoscopy [40].…”

Section: Additional Protein Markers Detectable In the Urinementioning

confidence: 99%

Urinary biomarkers in bladder cancer: A review of the current landscape and future directions

Stenzl

Sharma

et al. 2021

Urologic Oncology: Seminars and Original Investigations

144

120

View full text Add to dashboard Cite

ActionAdobe Reader version 9 Adobe Reader version X and XI Insert textClick the 'Text Edits' button on the Commenting tool bar. Click to set the cursor location in the text and simply start typing. The text will appear in a commenting box. You may also cut-and-paste text from another file into the commenting box. Close the box by clicking on 'x' in the top right-hand corner.Click the 'Insert Text' icon on the Comment tool bar. Click to set the cursor location in the text and simply start typing. The text will appear in a commenting box. You may also cut-and-paste text from another file into the commenting box. Close the box by clicking on '_' in the top right-hand corner. Replace text Replace textClick the 'Text Edits' button on the Commenting tool bar. To highlight the text to be replaced, click and drag the cursor over the text. Then simply type in the replacement text. The replacement text will appear in a commenting box. You may also cut-and-paste text from another file into this box. To replace formatted text (an equation for example) please Attach a file (see below).Click the 'Replace (Ins)' icon on the Comment tool bar. To highlight the text to be replaced, click and drag the cursor over the text. Then simply type in the replacement text. The replacement text will appear in a commenting box. You may also cut-and-paste text from another file into this box. To replace formatted text (an equation for example) please Attach a file (see below). Remove textClick the 'Text Edits' button on the Commenting tool bar. Click and drag over the text to be deleted. Then press the delete button on your keyboard. The text to be deleted will then be struck through.Click the 'Strikethrough (Del)' icon on the Comment tool bar. Click and drag over the text to be deleted. Then press the delete button on your keyboard. The text to be deleted will then be struck through. Highlight text/ make a commentClick on the 'Highlight' button on the Commenting tool bar. Click and drag over the text. To make a comment, double click on the highlighted text and simply start typing.Click on the 'Highlight Text' icon on the Comment tool bar. Click and drag over the text. To make a comment, double click on the highlighted text and simply start typing. Attach a fileClick on the 'Attach a File' button on the Commenting tool bar. Click on the figure, table or formatted text to be replaced. A window will automatically open allowing you to attach the file. To make a comment, go to 'General' in the 'Properties' window, and then 'Description'. A graphic will appear in the PDF file indicating the insertion of a file.Click on the 'Attach File' icon on the Comment tool bar. Click on the figure, table or formatted text to be replaced. A window will automatically open allowing you to attach the file. A graphic will appear indicating the insertion of a file. Leave a note/ commentClick on the 'Note Tool' button on the Commenting tool bar. Click to set the location of the note on the document and simply start typing. Do not use this feature to make text edits.C...

show abstract

Section: Additional Protein Markers Detectable In the Urinementioning

confidence: 99%

Urinary biomarkers in bladder cancer: A review of the current landscape and future directions

Stenzl

Sharma

et al. 2021

Urologic Oncology: Seminars and Original Investigations

144

120

View full text Add to dashboard Cite

show abstract

“…13,14 There are only a few studies on its efficacy in bladder TCC detection. In the preliminary study in 2014, Davis et al 11 showed that this method has 94% sensitivity and 89% specifity in 44 urine samples, particularly in low grade tumors. In 2018, a multicentric study by the same author showed that the overall sensitivity of CellDetect ® was 84% in 217 urine samples.…”

Section: Discussionmentioning

confidence: 99%

“…Normal bladder cells and TCC stain differently with CellDetect ® and can be differentiated morphologically. 10,11 The target of the stain is the cell nucleus. Benign epithelial cells are stained in greenish tones while malign cells are stained in red and its tones.…”

Section: Introductionmentioning

confidence: 99%

What is the role of CellDetect^® in detecting and monitoring bladder cancer?

et al. 2023

View full text Add to dashboard Cite

Purpose: Cystoscopy is the gold standard method for diagnosing and monitoring bladder cancer but it is costly, invasive, and operator-dependant. The aim is to compare the diagnostic efficacy of CellDetect® with urine cytology based on cystoscopic findings. Methods: A total of 181 patients undergoing cystoscopy for bladder cancer follow-up or any reason were studied with cytology and CellDetect® by taking an urine sample before cystoscopy. Patients who had any kind of bladder procedure in less than 1 month, doubtful cystoscopy results, previous pathology of Tis or carcinoma in situ (CIS), urinary stones, and patients with urinary catheters or bladder diversions were excluded. Cytologic and CellDetect® results were compared based on cystoscopic findings and sensitivity and specifity analyses were done for each method. Results: For low-grade tumors, the sensitivity of CellDetect® was 66.7% and the sensitivity of cytology was 16.7% with a significant difference ( p < 0.05). For high-grade tumors, there were no significant difference between CellDetect® and cytology. Generally, CellDetect® had better sensitivity in both case and control groups. Conclusion: The promising results of CellDetect® particularly in low-grade tumors gives the potential for this novel stain to go widespread. Larger series, meta-analyses, and reviews need to support this topic in order to put CellDetect® into daily practice.

show abstract

“…the bladder tumour-associated antigen (BTA) TRAK assay, nuclear matrix protein 22 (NMP22) and uCyt1 tests, have been approved by the United States Food and Drug Administration (FDA) but their utility is still very limited [15]. None of them have been incorporated in guidelines [16][17][18] and suffer from low sensitivity, especially for LGTs [19]. To improve cytology performance, new techniques have been also tested for harvesting intact urinaryexfoliated tumour cells, but the economic impact is high and the gain in term of sensitivity remains poor in cases with…”

Section: Discussionmentioning

confidence: 99%

Artificial intelligence to improve cytology performances in bladder carcinoma detection: results of the VisioCyt test

et al. 2021

View full text Add to dashboard Cite

To explore the utility of artificial intelligence (AI) using the VisioCytâ test (VitaDX International, Rennes, France) to improve diagnosis of bladder carcinoma using voided urine cytology. Patients and MethodsA national prospective multicentre trial (14 centres) was conducted on 1360 patients, divided in two groups. The first group included bladder carcinoma diagnosis with different histological grades and stages, and the second group included control patients based on negative cystoscopy and cytology results. The first step of this VISIOCYT1 trial focussed on algorithm development and the second step on validating this algorithm. A total of 598 patients were included in this first step, 449 patients with bladder tumours (219 high-grade and 230 low-grade) and 149 as negative controls. The VisioCyt test was compared to voided urine cytology performed by experienced uro-pathologists from each centre. ResultsOverall sensitivity was highly improved by the VisioCyt test compared to cytology (84.9% vs 43%). For high-grade tumours the VisioCyt test sensitivity was 92.6% vs 61.1% for the uro-pathologists. Regarding low-grade tumours, VisioCyt test sensitivity was 77% vs 26.3% for the uro-pathologists. ConclusionIn comparison to routine cytology, the results of the first phase of the VISIOCYT1 trial show very clear progress in terms of sensitivity, which is particularly visible and interesting for low-grade tumours. If the validation cohort confirms these results, it could lead to the VisioCyt test being considered as a very useful aid for pathologists. Moreover, as this test is in fact software based on AI, it should become more and more efficient as more data are collected.

show abstract

A Novel Urine Cytology Stain for the Detection and Monitoring of Bladder Cancer

Abstract: Findings show the capability of CellDetect to accurately identify urothelial carcinoma. This indicates that the technology can be further developed to provide an alternative urine cytology test with diagnostic value that may have significant clinical benefits.

Cited by 13 publications

References 14 publications

Urinary biomarkers in bladder cancer: A review of the current landscape and future directions

Urinary biomarkers in bladder cancer: A review of the current landscape and future directions

What is the role of CellDetect^® in detecting and monitoring bladder cancer?

Artificial intelligence to improve cytology performances in bladder carcinoma detection: results of the VisioCyt test

Contact Info

Product

Resources

About

A Novel Urine Cytology Stain for the Detection and Monitoring of Bladder Cancer

Abstract: Findings show the capability of CellDetect to accurately identify urothelial carcinoma. This indicates that the technology can be further developed to provide an alternative urine cytology test with diagnostic value that may have significant clinical benefits.

Cited by 13 publications

References 14 publications

Urinary biomarkers in bladder cancer: A review of the current landscape and future directions

Urinary biomarkers in bladder cancer: A review of the current landscape and future directions

What is the role of CellDetect® in detecting and monitoring bladder cancer?

Artificial intelligence to improve cytology performances in bladder carcinoma detection: results of the VisioCyt test

Contact Info

Product

Resources

About

What is the role of CellDetect^® in detecting and monitoring bladder cancer?